Characteristics | Patients |
N=32 | |
Gender | |
Female | 18 (56.3) |
Male | 14 (43.8) |
Age, years | |
Median (range) | 62 (35–77) |
<65 | 20 (62.5) |
≥65 | 12 (37.5) |
ECOG PS | |
0 | 24 (75.0) |
1 | 8 (25.0) |
Lactate dehydrogenase | |
Normal | 21 (65.6) |
Elevated | 11 (34.4) |
Primary site | |
Head and neck | 17 (53.1) |
Esophagus | 2 (6.3) |
Vagina and cervix | 7 (21.9) |
Rectum* | 6 (18.8) |
Disease stage | |
Stage III | 10 (31.3) |
Stage IV | 22 (68.8) |
Metastatic site | |
Lymph node | 14 (43.8) |
Lung | 11 (34.4) |
Liver | 7 (21.9) |
Others† | 12 (37.5) |
Gene mutation | |
BRAF | 2/26 (7.7) |
KIT | 3/26 (11.5) |
NRAS | 8/26 (30.8) |
TPS | |
<1 | 20/24 (83.3) |
≥1 | 4/24 (16.7) |
TMB | |
Median (range) | 4 (0–7.4) |
Low (<4 muts/Mb) | 12/25 (48.0) |
High (≥4 muts/Mb) | 13/25 (52.0) |
Prior treatment | |
Yes | 16 (50.0) |
No | 16 (50.0) |
Values are numbers and percentages unless otherwise noted. PD-L1 expression was evaluated by 22C3 immunohistochemistry staining.
*Three cases were rectal above the dentate line and three were anal canal below the dentate line
†Other metastatic sites included: four bone, four abdominopelvic cavity, three subcutaneous soft tissue, two pleura, two stomach, two pancreas, one adrenal gland, one small intestine, one parotid gland, one kidney; there were no brain metastases.
ECOG PS, Eastern Cooperative Oncology Group performance status; TMB, tumor mutation burden; TPS, tumor proportion score.